MD Buyline released a report highlighting emerging soft tissue robotic technologies and their financial and clinical considerations. The report discusses the cost of ownership for current and future robotic systems, weighing increased surgical costs against reduced length of stay benefits. It also provides a break-even analysis for four scenarios examining how purchase prices, reimbursement rates, and other factors affect financial outcomes. The report covers clinical outcomes for urology and gynecology procedures and vendors developing next-generation soft tissue robotics.